Current developments in nucleoside/nucleotide analogues for hepatitis B. - Wikidata - awgldk - TriplyDB

Current developments in nucleoside/nucleotide analogues for hepatitis B.

Current developments in nucleoside/nucleotide analogues for hepatitis B.

http://www.wikidata.org/entity/Q38208628

about

Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening.Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis.Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B.Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B.A Series of Oleanolic Acid Derivatives as Anti-Hepatitis B Virus Agents: Design, Synthesis, and in Vitro and in Vivo Biological Evaluation.Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.Effects of Rubiadin isolated from Prismatomeris connata on anti-hepatitis B virus activity in vitro.

P2860

Q28551711-996DD2A6-214F-4DAB-B048-C7128815D806 Q35694422-15724B6A-9587-40E6-899D-6DA86129760C Q36346801-8DC73206-1500-47CD-94D4-3A73A2E0C200 Q37421489-2B399575-451A-418C-8ED0-964C9B6B9C23 Q38260502-B69DD012-D551-499C-AEDA-C758EB820F70 Q38268743-1FECABF5-6E76-4E81-8472-41AA9FFD0900 Q38940522-3275034A-440D-4ECC-B5F9-6E745B7B62C8 Q40528074-F3A1A9B9-1ED2-4688-B2A5-C346B183FABB Q40737218-D4973A36-014F-4E66-9362-7B4FA9964B2B Q40940224-0AE3F39A-864E-4D6A-89AF-2EAD06537D4D Q45326143-9A695C8F-2A0F-434F-BC02-109EF95FC501

P2860

Current developments in nucleoside/nucleotide analogues for hepatitis B.

http://www.wikidata.org/entity/Q38208628

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current developments in nucleoside/nucleotide analogues for hepatitis B.

@en

type

label

Current developments in nucleoside/nucleotide analogues for hepatitis B.

@en

prefLabel

Current developments in nucleoside/nucleotide analogues for hepatitis B.

@en

P1433

Q38208628-47E0F443-F444-4AF4-8993-53369DB10951

P1476

Q38208628-9D764046-4989-461B-93CF-0C2DC439C42A

P2093

Q38208628-8B7D0011-19A8-4030-9F54-AA26335CAF27

Q38208628-CCD59A2F-C499-46B6-A7D6-A82810CA4FA7

P2860

Q38208628-00E1D9DF-9F44-42D5-8A03-4D5FF3E92010

Q38208628-01BA6406-648F-4CBE-8F01-D553A7F3AD5B

Q38208628-02907B06-3566-4875-B729-A1B9B047BD00

Q38208628-02F198A7-2AA9-427F-B9C0-D49C05832D21

Q38208628-04AB7A16-DBAC-4E86-9E8E-36DC08D2EAF7

Q38208628-057B4988-71AF-480C-AA4D-7D70CED57828

Q38208628-0980CA5B-5263-497B-851E-C773954DCDA1

Q38208628-09980CDD-4AEF-4073-BDC9-5FF122C1D99A

Q38208628-0A3581A6-E20F-4A27-850B-FFC62B185885

Q38208628-0A4EF977-1378-4F5B-B99C-17758EC64C8E

P304

Q38208628-12191AA4-2F5B-4903-9D13-FCE66522F391

P31

Q38208628-893A70CC-9984-4FBB-8B0D-7A7870B2515B

P356

Q38208628-EE85759F-1005-4C98-A50F-EA22D992ADFF

P433

Q38208628-99BF3221-AC7D-449E-B2F4-489865FBBCE4

P478

Q38208628-FDB318B2-A97A-4A51-9E69-D316AD42E311

P577

Q38208628-3E595209-0E29-4ECF-AD51-3B5BE7200D96

P698

Q38208628-CE047098-DC1C-425D-A8B7-3951F6600AEE

P356

17474124.2014.909724

P1433

Expert Review of Gastroenterology & Hepatology

P1476

Current developments in nucleoside/nucleotide analogues for hepatitis B.

@en

P2093

Angeline Oi-Shan Lo

http://www.w3.org/2001/XMLSchema#string

Grace Lai-Hung Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

Telbivudine versus lamivudine in patients with chronic hepatitis B

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chronic hepatitis B: update 2009

Transient elastography: Kill two birds with one stone?

Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus.

Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease.

P304

607-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474124.2014.909724

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24787673

http://www.w3.org/2001/XMLSchema#string